4.72

10.80% 0.46

After Hours: 4.55 -0.17 -3.60%

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $4.72, with a volume of 774.80K. It is up +10.80% in the last 24 hours and down -16.16% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Previous Close:

$4.26

Open:

$4.27

24h Volume:

774.80K

Relative Volume:

0.72

Market Cap:

$229.10M

Revenue:

Net Income/Loss:

$-67.68M

P/E Ratio:

-2.7283

EPS:

-1.73

Net Cash Flow:

$-54.24M

1W Performance:

+8.01%

1M Performance:

-16.16%

6M Performance:

-72.33%

1Y Performance:

-68.99%

1-Day Range:

$4.17

$4.77

1-Week Range:

$3.81

$4.77

52-Week Range:

$3.4713

$26.35

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

138

Twitter

@CabalettaBio

Next Earnings Date

2024-08-08

Latest SEC Filings

CABA's Discussions on Twitter

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

04:52 AM

Cabaletta Bio secures lease terms through August 2026 By Investing.com - Investing.com Australia

04:52 AM

11:58 AM

Ratios Reveal: Breaking Down Cabaletta Bio Inc (CABA)’s Financial Health - The Dwinnex

11:58 AM

04:18 AM

Perceptive Advisors LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

04:18 AM

Sep 27, 2024

Wall Street SWOT: Cabaletta Bio stock pioneers CAR-T in immunology amid challenges - Investing.com

Sep 27, 2024

Lynx1 Capital Management LP Has $3.68 Million Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Sep 27, 2024

Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MSN

Sep 27, 2024

Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MyChesCo

Sep 27, 2024

Sep 26, 2024

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 - ForexTV.com

Sep 26, 2024

Deerfield Management Company L.P. Series C Reduces Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Sep 26, 2024

Sep 25, 2024

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR - EIN News

Sep 25, 2024